Coronary artery disease
Conditions
Interventions
PTS with microcirculation disorder:N/A
PTS without microcirculation disorder:N/A
non-PTS with microcirculation disorder:N/A
non-PTS without microcirculation disorder:N/A
Sponsors
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Case group: (1) patients with stable coronary artery disease (who have been confirmed to have at least one stenosis more than 50% inner diameter of coronary artery via coronary angiogram); (2) patients who aged 18 to 70; (3) patients who conform to anyone of the following grouping criteria: PTS with microcirculation disorder: maximum platelet aggregation rate (MPAR)>65% with moderate or severe disorder of nailfold microcirculation; PTS without microcirculation disorder: MPAR>65% with normal or mild disorder of nailfold microcirculation; non-PTS with microcirculation disorder: MPAR=65% with moderate or severe disorder of nailfold microcirculation; non-PTS without microcirculation disorder: MPAR=65% with normal or mild disorder of nailfold microcirculation; (4) patients who are well- informed and sign the informed consent. Healthy control: (1) people who aged 18 to 70 and there is no gender limitation; (2) people who have no medical history of infectious, psychiatric or physical disease; (3) people who have been confirmed to have no manifested psychiatric or physical problems through detailed medical history enquiry, blood biochemical tests and physical examination; (4) people who have normal MPAR (MPAR<65%) and nailfold microcirculation; (5) people who are well- informed and sign the informed consent.
Exclusion criteria
Exclusion criteria: Case group: (1) patients who are combined with infection, fever, trauma or surgery within 1 month; (2) patients who are combined with acute cerebrovascular disease within 6 months; (3) patients who are combined with active rheumatic autoimmune disease, active tuberculosis, cancer or organ transplantation; (4) patients who are combined with severe hepatic-renal, hematopoietic or mental disorders; (5) pregnant or lactating women. Healthy control: (1) people who currently participate in another clinical trial; (2) people who are combined with infection, fever, trauma or surgery within 1 month; (3) people who currently take any cardioactive medicine or herb; (4) pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| microRNA; | — |
Countries
China
Contacts
Public ContactShi Dazhuo
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed